3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
venetoclax
157
Cytarabine
117
Cyclophosphamide
110
Specimen Handling
103
Azacitidine
103
fludarabine
89
Biopsy
78
Rituximab
50
Methotrexate
45
Daunorubicin
45
fludarabine phosphate
41
Vincristine
38
Dexamethasone
37
Injections
36
Magnetic Resonance Spectroscopy
35
Decitabine
35
Granulocyte Colony-Stimulating Factor
32
blinatumomab
31
Mycophenolic Acid
30
Idarubicin
30
Whole-Body Irradiation
29
ibrutinib
27
Tacrolimus
27
Prednisone
27
Etoposide
27
Doxorubicin
27
Busulfan
27
acalabrutinib
24
Melphalan
24
Filgrastim
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cobicistat
×
Other hematologic neoplasm
×
90 days
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA